Roughly 45 ENDS products hold FDA marketing authorization as of August 2026, from five companies: Vuse, JUUL, NJOY, Logic and Glas. FDA's tobacco products marketing orders page is the authoritative list and is worth checking directly rather than trusting a count in an article, this one included. Against that handful, marketing denial orders and refuse-to-accept decisions have covered millions of products. The gap between authorized and denied is not primarily about product quality. It is about documentation.
Two documents govern that documentation, and it matters which is which. 21 CFR Part 1114 is a binding regulation. FDA's finalized ENDS PMTA guidance is not: like all FDA guidance, it represents the agency's current thinking and creates no legally enforceable obligation on anyone. What it does is tell you how reviewers will read an application, which in practice is close to decisive. At the February 2026 ENDS Roundtable, FDA's Center for Tobacco Products reinforced the same message: there is no realistic path to a single static list of acceptable ingredients, so every application must stand on its own scientific completeness.
For nicotine ingredient buyers, that position changes the sourcing calculus. Your supplier's documentation is not supplementary to your PMTA. It is foundational. If your nicotine supplier cannot produce CAS numbers, purity specifications with defined acceptance ranges, stability data, and HPHC characterization on demand, your application has a structural vulnerability that no amount of product-side testing can close.
What Is Required Per Ingredient, and What Is Only Expected
The guidance, originally drafted in 2016 and finalized in June 2019, identifies product characterization as the foundational basis for PMTA review and APPH (Appropriate for the Protection of Public Health) determinations. The core ingredient documentation framework survived from draft to final with minimal changes.
The binding core sits in 21 CFR 1114.7(i), which requires the following for each ingredient in an e-liquid formulation:
- Ingredient name (IUPAC or common name)
- CAS number (Chemical Abstracts Service registry number)
- Purity/grade and supplier identification
- Target quantity and acceptable range with unit of measure (e.g., mg/mL or mg/unit)
- Complex ingredient breakdown: each single chemical substance reported separately with all required information
For nicotine specifically, the guidance recommends additional characterization. These are not separate regulatory line items; they are what FDA looks for when it evaluates whether the product is adequately characterized:
- pH of the finished formulation
- Nicotine form information (unprotonated/freebase vs. nicotine salts)
- Nicotine quantity with clear targets and acceptance ranges
- Nicotine, moisture, and pH parameters as part of chemistry design information
The first list is a regulatory requirement. The second is FDA's expectation, expressed through non-binding guidance. In review, the practical difference is small: an application missing the guidance items is an application a reviewer cannot fully characterize, and that generates a deficiency finding either way. The difference matters when a supplier tells you something is legally mandated. Ask which instrument says so.
Stability, HPHC, and Microbial Testing: The Three Data Pillars
Beyond basic ingredient identification, the guidance establishes three testing categories that directly implicate nicotine ingredient suppliers.
Stability Testing
The guidance recommends measurements at the beginning, middle, and end of the product's proposed shelf life. For nicotine ingredients, this means the supplier should be able to provide stability data demonstrating that purity specifications, nicotine content, and pH parameters hold through the claimed shelf-life period. If your supplier provides a 24-month shelf-life claim on their USP/EP grade nicotine but cannot produce real-time stability study data supporting that claim, the gap will surface during PMTA review.
HPHC Analysis
Harmful and Potentially Harmful Constituents testing must use validated methods on the specific product type. For nicotine ingredients, the relevant HPHCs include Tobacco Specific Nitrosamines (TSNAs), carbonyls, and heavy metals. The nicotine ingredient's contribution to the finished product's HPHC profile must be documentable and attributable. Suppliers who provide batch-level HPHC data give their customers a direct pathway to meeting this requirement. Suppliers who do not force the manufacturer to test in isolation and attempt to back-calculate ingredient contributions, a less precise and more time-consuming approach.
Microbial Testing
The guidance recommends beta-glucan and endotoxin testing for e-liquid products. For nicotine ingredients supplied in liquid form, including nicotine dilutions in VG or PG carriers, microbial contamination data at the ingredient level supports the manufacturer's finished-product testing program.
The February 2026 Roundtable: What Reviewers Said They Look For
On February 10, 2026, FDA's Center for Tobacco Products hosted a roundtable for small ENDS manufacturers, open to firms with fewer than 350 employees. Nothing said at a roundtable is binding, and FDA issued no guidance out of it. What it produced was a clear readout of how reviewers are thinking, which is worth taking seriously when it bears on sourcing decisions.
No safe ingredient list. FDA indicated there is no realistic path to a pre-approved ingredient list. Each ingredient in each application is evaluated independently based on the data submitted. This means a nicotine supplier's documentation must be application-ready for every customer, not based on a general assumption that nicotine is "known safe."
Quality systems must be demonstrably operational. FDA distinguished between having Standard Operating Procedures on paper and having completed documentation showing those systems actually work. Real batch release data and in-process controls are the standard, not theoretical quality manuals.
Toxicology carries equal weight. The APPH determination weighs toxicology equally with product design and manufacturing controls. FDA applies a conservative 1.5 micrograms/day Threshold of Toxicological Concern (TTC) when data are limited and uses an Excess Lifetime Cancer Risk (ELCR) framework with emphasis on inhalation route relevance.
Dynamic hazard evaluation. Assessments cannot remain static. FDA expects applicants to reflect current scientific judgment, which means ingredient documentation must be updated as new data emerges, not filed once and forgotten.
For nicotine ingredient buyers, the roundtable message was unambiguous: the documentation your supplier provides is not peripheral to your PMTA. It is a core component of the APPH evaluation.
Tobacco Product Master Files: The Documentation Shortcut Most Suppliers Miss
A Tobacco Product Master File (TPMF) is a confidential submission that allows a supplier to file proprietary ingredient information directly with FDA. The PMTA applicant references the TPMF via an authorization letter. FDA reviews the TPMF content during evaluation without disclosing it to the applicant or the public.
For nicotine ingredient suppliers, a TPMF serves two functions:
- IP protection. Proprietary process details, purity specifications, and manufacturing data stay confidential. The customer gets the benefit of the documentation in their PMTA without the supplier revealing trade secrets.
- Documentation completeness. A comprehensive TPMF pre-positions all required ingredient data with FDA. When a customer's PMTA references it, FDA can evaluate the ingredient documentation immediately rather than issuing deficiency letters requesting information the applicant may not have.
Without a supplier TPMF, the manufacturer must independently document all ingredient details. That typically means less precise data, more back-and-forth with the supplier, and weaker IP protection for both parties.
If your current nicotine supplier does not maintain a TPMF with FDA, ask why. To be clear about its status: a TPMF is entirely voluntary. No rule requires a supplier to file one, and no application is defective for lacking a referenced master file. It is a competitive differentiator rather than a compliance obligation, and it directly affects how quickly their customers' ingredient sections can be reviewed.
The March 2026 Flavored ENDS Draft Guidance Raises the Evidence Bar
FDA published draft guidance on flavored ENDS in the Federal Register on March 11, 2026 (docket FDA-2026-D-1817). It is a draft, which means it is not FDA's settled position and binds nobody. It does not replace the base PMTA requirements. It sketches a graduated risk-proportionate framework on top of them.
| Flavor Category | Youth Risk Level | Evidentiary Burden |
|---|---|---|
| Fruit, candy, dessert, sweet | High | Substantial evidence of adult switching benefit |
| Menthol, mint | Moderate | More modest incremental showing |
| Coffee, tea, spices | Lower | May satisfy with lower-risk demonstration |
| Tobacco | Baseline | Standard PMTA requirements |
The comment period closed May 11, 2026, and the guidance remains in draft as of August 2026. For nicotine ingredient suppliers, it signals that customers formulating flavored ENDS products will need more robust ingredient documentation to meet the higher evidentiary burdens for high-risk flavor categories. Purity data, contaminant profiles, and stability testing become more critical when the overall application must clear a higher bar.
The context here changed in 2026 and is often reported out of date. On May 5, 2026, FDA authorized four Glas pod products, including a mango and a blueberry variant. Those were the first non-tobacco, non-menthol ENDS products ever authorized in the United States, and the orders were tied to device-level age-gating technology. So the old line that no flavored ENDS beyond menthol has ever been authorized is no longer true, though the number remains very small and the authorizations came with conditions attached to the hardware.
What has not changed is the judicial position. The Supreme Court's unanimous decision in FDA v. Wages and White Lion Investments (April 2, 2025) held that FDA's denials of flavored ENDS applications were not arbitrary and capricious. The Court vacated the Fifth Circuit's contrary ruling and remanded on a narrower question about whether the matter should go back to FDA. FDA's authority to deny on the evidence remains intact.
The Enforcement Math: $200 Million and Counting
FDA's enforcement posture makes documentation quality an existential business concern, not just a compliance exercise.
Section 772 of the FY2026 appropriations legislation directs at least $200 million of tobacco user-fee collections toward enforcement against unauthorized ENDS products. Two rules that would tighten things further are still only proposals. The ACE (Automated Commercial Environment) rule would require PMTA tracking numbers at the port of entry for imported products; comments closed in October 2024 and no final rule has issued. The Tobacco Product Manufacturing Practices rule, which would formalize GMP-like manufacturing standards, was proposed in March 2023 and remains unfinalized more than three years later. Neither imposes an obligation today.
For manufacturers relying on nicotine ingredient suppliers with incomplete documentation, the enforcement trajectory creates compounding risk. An unauthorized product is not just legally vulnerable. It is commercially exposed to enforcement actions that can remove it from the market entirely.
What Nicotine Ingredient Buyers Should Demand from Suppliers
The finalized ENDS PMTA guidance, reinforced by the February roundtable and layered with the March flavored guidance, establishes a clear documentation standard. Here is what your nicotine supplier should be able to provide:
- Certificates of Analysis with full analytical data per batch, including assay percentage, impurity profiles, and grade certification. Not just pass/fail.
- CAS numbers and IUPAC names for nicotine and every sub-component.
- Purity/grade specifications with defined acceptance ranges supported by real batch release data.
- Nicotine form characterization: freebase vs. salt, protonation state, pH, and form-specific documentation for products like nicotine bitartrate dihydrate.
- Stability data from real-time studies supporting shelf-life claims.
- HPHC testing data including TSNAs, carbonyls, and heavy metals at the ingredient level.
- Microbial testing (beta-glucan, endotoxin) for liquid-form nicotine.
- TPMF availability for confidential cross-referencing in customer PMTAs.
- Batch-to-batch consistency data with statistical process control documentation.
- Supply chain traceability from raw material origin through final delivery.
No rule sets a turnaround time for any of this. FDA does not audit your supplier and does not care how fast a CoA arrives. Response speed matters for a commercial reason instead: when FDA issues an information request mid-review, the clock that matters is your customer's, and a supplier who takes weeks to answer turns a routine request into a filing risk. Treat a same-week turnaround on items 1 through 6 as a procurement standard you set, not a regulatory one you inherit.
For a deeper analysis of how nicotine sourcing decisions affect PMTA submissions, see PMTA Requirements: How Your Nicotine Source Affects FDA Submissions. For background on the PMTA fast-track pilot for nicotine pouches, which streamlined review procedure without relaxing the evidence required, that analysis covers the full timeline.
Frequently Asked Questions
What ingredient documentation does FDA's ENDS PMTA guidance require for nicotine?
The binding requirement sits in 21 CFR 1114.7(i): ingredient name (IUPAC or common name), CAS number, purity/grade with supplier identification, and target quantity with acceptable range, with each chemical substance in a complex ingredient reported separately. FDA's finalized ENDS PMTA guidance layers on recommendations rather than requirements, including nicotine form characterization (freebase vs. salt, pH, protonation state), stability testing across the proposed shelf life, HPHC analysis using validated methods, and microbial testing for e-liquid products. Guidance is not legally binding, but an application that ignores it is an application a reviewer cannot fully characterize.
What did FDA mean by "no universal ingredient safe list" at the February 2026 roundtable?
At the February 10, 2026 ENDS Roundtable, FDA indicated there is no realistic path to a pre-approved list of acceptable ingredients for ENDS products. Each ingredient in each PMTA is evaluated independently based on the toxicological and characterization data submitted in that specific application. This means nicotine suppliers cannot rely on a general assumption that nicotine is "known safe" and should provide application-ready documentation for each customer's submission. Statements made at a roundtable are not binding guidance; they indicate how reviewers are approaching applications.
What is a Tobacco Product Master File and why does it matter for nicotine suppliers?
A Tobacco Product Master File (TPMF) is a confidential submission that allows a nicotine ingredient supplier to file proprietary formulation and process data directly with FDA. PMTA applicants reference the TPMF via an authorization letter, and FDA reviews the data without disclosing it to the applicant. A TPMF protects supplier IP while strengthening the customer's PMTA with complete, pre-positioned ingredient documentation. Without one, manufacturers must independently document all ingredient details, typically with less precision.
How does the March 2026 flavored ENDS draft guidance affect nicotine ingredient documentation?
The March 2026 draft guidance (FDA-2026-D-1817), published in the Federal Register on March 11, 2026, sketches a graduated risk framework on top of existing PMTA requirements. It is a draft and binds nobody; the comment period closed May 11, 2026. Flavored ENDS products in high-risk categories (fruit, candy, dessert) would face substantially higher evidentiary burdens, which raises the importance of robust ingredient documentation including purity data, contaminant profiles, and stability testing. Note that the frequently repeated claim that no flavored ENDS beyond menthol has been authorized is out of date: FDA authorized four Glas pod products on May 5, 2026, including mango and blueberry variants, tied to device-level age-gating. The Supreme Court has separately upheld FDA's authority to deny flavored applications on the evidence, so the documentation bar for these products remains the highest in the ENDS category.
The regulatory direction is clear. FDA is building an authorized-only marketplace backed by at least $200 million in appropriated enforcement funding, a unanimous Supreme Court decision affirming its authority to deny applications on the evidence, and documentation standards that leave no room for incomplete ingredient data. The suppliers who position their customers for successful PMTAs are the ones providing full analytical documentation, TPMF cross-referencing, and batch-level traceability as standard practice.
NicAlliance provides USP/EP grade nicotine with full Certificate of Analysis documentation, stability data, and supply chain traceability backed by a certified US-based manufacturing partner. If your current supplier's documentation cannot support the standards outlined in this guidance, request a sample with full CoA and compare.